CD274 and gastroesophageal junction adenocarcinoma: Maintenance therapy using anti-PD-L1 (MEDI4736) in locally advanced and metastatic GEJ adenocarcinoma after the standard first-line treatment is currently being investigated in a phase II trial [124].